Anna Rosell Novel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7699277/publications.pdf

Version: 2024-02-01

99 papers	5,830 citations	71061 41 h-index	79644 73 g-index
100 all docs	100 docs citations	100 times ranked	7570 citing authors

#	Article	IF	Citations
1	Endovascular administration of magnetized nanocarriers targeting brain delivery after stroke. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 237-252.	2.4	9
2	Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke. Neurotherapeutics, 2022, 19, 513-527.	2.1	2
3	Central nervous system delivery of molecules across the blood-brain barrier. Neurochemistry International, 2021, 144, 104952.	1.9	55
4	Angiogenin in the Neurogenic Subventricular Zone After Stroke. Frontiers in Neurology, 2021, 12, 662235.	1.1	5
5	Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction. Bioactive Materials, 2021, 6, 3314-3327.	8.6	40
6	Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke. Frontiers in Neurology, 2021, 12, 767484.	1.1	2
7	Blood-based biomarkers and stem cell therapy in human stroke: a systematic review. Molecular Biology Reports, 2020, 47, 6247-6258.	1.0	3
8	A Mouse Brain-based Multi-omics Integrative Approach Reveals Potential Blood Biomarkers for Ischemic Stroke. Molecular and Cellular Proteomics, 2020, 19, 1921-1936.	2.5	20
9	PLGA protein nanocarriers with tailor-made fluorescence/MRI/PET imaging modalities. Nanoscale, 2020, 12, 4988-5002.	2.8	22
10	Matrix metalloproteinases and ADAMs in stroke. Cellular and Molecular Life Sciences, 2019, 76, 3117-3140.	2.4	43
11	Combining magnetic nanoparticles and icosahedral boron clusters in biocompatible inorganic nanohybrids for cancer therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 101986.	1.7	27
12	Endothelial Progenitor Cell Secretome and Oligovascular Repair in a Mouse Model of Prolonged Cerebral Hypoperfusion. Stroke, 2018, 49, 1003-1010.	1.0	66
13	Merging Icosahedral Boron Clusters and Magnetic Nanoparticles: Aiming toward Multifunctional Nanohybrid Materials. Inorganic Chemistry, 2018, 57, 462-470.	1.9	24
14	Protective Effects of Endothelial Progenitor Cell-Derived Extracellular Mitochondria in Brain Endothelium. Stem Cells, 2018, 36, 1404-1410.	1.4	106
15	Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology. Scientific Reports, 2018, 8, 7899.	1.6	17
16	Importance of Angiogenin and Endothelial Progenitor Cells After Rehabilitation Both in Ischemic Stroke Patients and in a Mouse Model of Cerebral Ischemia. Frontiers in Neurology, 2018, 9, 508.	1.1	20
17	Revascularization and endothelial progenitor cells in stroke. American Journal of Physiology - Cell Physiology, 2018, 315, C664-C674.	2.1	41
18	New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. Cardiovascular Research, 2017, 113, 1219-1229.	1.8	15

#	Article	IF	Citations
19	The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments). Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3488-3517.	2.4	128
20	Profiling and identification of new proteins involved in brain ischemia using MALDI-imaging-mass-spectrometry. Journal of Proteomics, 2017, 152, 243-253.	1.2	23
21	Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. International Journal of Nanomedicine, 2016, Volume 11, 3035-3048.	3.3	56
22	Plasma Matrix Metalloproteinases in Patients With Stroke During Intensive Rehabilitation Therapy. Archives of Physical Medicine and Rehabilitation, 2016, 97, 1832-1840.	0.5	17
23	Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice. Neurobiology of Disease, 2016, 91, 236-246.	2.1	25
24	Encapsulation of VEGF₁₆₅into magnetic PLGA nanocapsules for potential local delivery and bioactivity in human brain endothelial cells. Journal of Materials Chemistry B, 2015, 3, 2538-2544.	2.9	25
25	Endothelial progenitor cells and revascularization following stroke. Brain Research, 2015, 1623, 150-159.	1.1	44
26	Impaired Vascular Remodeling after Endothelial Progenitor Cell Transplantation in MMP9-Deficient Mice Suffering Cortical Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1547-1551.	2.4	31
27	Development of a neuroprotective peptide that preserves survival pathways by preventing Kidins220/ARMS calpain processing induced by excitotoxicity. Cell Death and Disease, 2015, 6, e1939-e1939.	2.7	27
28	NURR1 Involvement in Recombinant Tissue-Type Plasminogen Activator Treatment Complications After Ischemic Stroke. Stroke, 2015, 46, 477-484.	1.0	14
29	Fluorescent Molecular Peroxidation Products. Stroke, 2014, 45, 432-437.	1.0	10
30	In vitro angiogenic performance and in vivo brain targeting of magnetized endothelial progenitor cells for neurorepair therapies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 225-234.	1.7	53
31	Rapid synthesis of water-dispersible superparamagnetic iron oxide nanoparticles by a microwave-assisted route for safe labeling of endothelial progenitor cells. Acta Biomaterialia, 2014, 10, 3775-3785.	4.1	57
32	Mild hypothermia protects against oxygen glucose deprivation (OGD)-induced cell death in brain slices from adult mice. Journal of Neural Transmission, 2014, 121, 113-117.	1.4	5
33	Brain proteomics identifies potential simvastatin targets in acute phase of stroke in a rat embolic model. Journal of Neurochemistry, 2014, 130, 301-312.	2.1	25
34	Chemokines after human ischemic stroke: From neurovascular unit to blood using protein arrays. Translational Proteomics, 2014, 3, 1-9.	1.2	18
35	Intra-Arterial Bone Marrow Mononuclear Cell Transplantation Correlates with GM-CSF, PDGF-BB, and MMP-2 Serum Levels in Stroke Patients: Results from a Clinical Trial. Cell Transplantation, 2014, 23, 57-64.	1.2	35
36	Rat Middle Cerebral Artery Occlusion Is Not a Suitable Model for the Study of Stroke-Induced Spontaneous Infections. PLoS ONE, 2014, 9, e99169.	1.1	2

#	Article	IF	Citations
37	Distal Occlusion of the Middle Cerebral Artery in Mice: Are We Ready to Assess Long-Term Functional Outcome?. Translational Stroke Research, 2013, 4, 297-307.	2.3	55
38	The angiogenic gene profile of circulating endothelial progenitor cells from ischemic stroke patients. Vascular Cell, 2013, 5, 3.	0.2	18
39	From brain to blood: New biomarkers for ischemic stroke prognosis. Journal of Proteomics, 2013, 94, 138-148.	1.2	28
40	Decreased Levels of Angiogenic Growth Factors in Intracranial Atherosclerotic Disease despite Severity-Related Increase in Endothelial Progenitor Cell Counts. Cerebrovascular Diseases, 2013, 35, 81-88.	0.8	16
41	Cerebral ischaemia and matrix metalloproteinaseâ€9 modulate the angiogenic function of early and late outgrowth endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 2013, 17, 1543-1553.	1.6	34
42	Combining Statins with Tissue Plasminogen Activator Treatment After Experimental and Human Stroke: A Safety Study on Hemorrhagic Transformation. CNS Neuroscience and Therapeutics, 2013, 19, 863-870.	1.9	10
43	Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. Pharmacogenomics, 2013, 14, 495-504.	0.6	18
44	Pannexins after stroke. Channels, 2013, 7, 59-59.	1.5	0
45	Factors Secreted by Endothelial Progenitor Cells Enhance Neurorepair Responses after Cerebral Ischemia in Mice. PLoS ONE, 2013, 8, e73244.	1.1	93
46	Lipoprotein-Associated Phospholipase A₂ Activity Is Associated with Large-Artery Atherosclerotic Etiology and Recurrent Stroke in TIA Patients. Cerebrovascular Diseases, 2012, 33, 150-158.	0.8	36
47	Brain Natriuretic Peptide Is Associated with Worsening and Mortality in Acute Stroke Patients but Adds No Prognostic Value to Clinical Predictors of Outcome. Cerebrovascular Diseases, 2012, 34, 240-245.	0.8	32
48	Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients. Stroke, 2012, 43, 1398-1400.	1.0	13
49	A new method for focal transient cerebral ischaemia by distal compression of the middle cerebral artery. Neuropathology and Applied Neurobiology, 2012, 38, 617-627.	1.8	38
50	Citicoline in preâ€clinical animal models of stroke: a metaâ€analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. Journal of Neurochemistry, 2012, 123, 217-225.	2.1	29
51	Evidence for the efficacy of statins in animal stroke models: a metaâ€analysis. Journal of Neurochemistry, 2012, 122, 233-243.	2.1	70
52	Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. Journal of Proteomics, 2012, 75, 4758-4765.	1.2	68
53	Intra-Arterial Bone Marrow Mononuclear Cells in Ischemic Stroke. Stroke, 2012, 43, 2242-2244.	1.0	208
54	The gender gap in stroke: a meta-analysis. Acta Neurologica Scandinavica, 2012, 125, 83-90.	1.0	70

#	Article	IF	Citations
55	A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis, 2011, 216, 205-211.	0.4	103
56	Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis, 2011, 218, 181-187.	0.4	24
57	Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage. PLoS ONE, 2011, 6, e16750.	1.1	60
58	A panel of biomarkers including caspase-3 and D-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department. Journal of Internal Medicine, 2011, 270, 166-174.	2.7	61
59	Leukoaraiosis is associated with genes regulating blood-brain barrier homeostasis in ischaemic stroke patients. European Journal of Neurology, 2011, 18, 826-835.	1.7	24
60	Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Research, 2011, 1373, 211-220.	1.1	24
61	Osteopontin predicts long-term functional outcome among ischemic stroke patients. Journal of Neurology, 2011, 258, 486-493.	1.8	23
62	The Proteome of Human Brain After Ischemic Stroke. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1105-1115.	0.9	43
63	Blood biomarkers to identify ischemic stroke etiologies. Therapy: Open Access in Clinical Medicine, 2010, 7, 337-353.	0.2	1
64	Oxidative Stress After Thrombolysis-Induced Reperfusion in Human Stroke. Stroke, 2010, 41, 653-660.	1.0	83
65	Reperfusion Therapy for Acute Stroke Improves Outcome by Decreasing Neuroinflammation. Translational Stroke Research, 2010, 1, 261-267.	2.3	9
66	Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. Journal of Neurochemistry, 2010, 112, 134-149.	2.1	118
67	Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke. Stroke, 2010, 41, 1528-1535.	1.0	66
68	Metalloproteinase and stroke infarct size: role for antiâ€inflammatory treatment?. Annals of the New York Academy of Sciences, 2010, 1207, 123-133.	1.8	133
69	Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvascular Research, 2010, 80, 317-323.	1.1	69
70	Blood Biomarkers in Cardioembolic Stroke. Current Cardiology Reviews, 2010, 6, 194-201.	0.6	16
71	Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thrombosis and Haemostasis, 2009, 102, 759-764.	1.8	19
72	Endogenous Activated Protein C Predicts Hemorrhagic Transformation and Mortality after Tissue Plasminogen Activator Treatment in Stroke Patients. Cerebrovascular Diseases, 2009, 28, 143-150.	0.8	23

#	Article	IF	Citations
73	Plasma and Brain Matrix Metalloproteinase-9 After Acute Focal Cerebral Ischemia in Rats. Stroke, 2009, 40, 2836-2842.	1.0	121
74	Neuronal TIMPâ€1 release accompanies astrocytic MMPâ€9 secretion and enhances astrocyte proliferation induced by Î²â€amyloid 25â€“35 fragment. Journal of Neuroscience Research, 2009, 87, 2115-2125.	1.3	34
75	Matrix Metalloproteinase-13 is Activated and is found in the Nucleus of Neural Cells after Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 398-410.	2.4	61
76	Neuregulin-1 Signaling in Brain Endothelial Cells. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 39-43.	2.4	44
77	Interleukin-1Î² Augments Angiogenic Responses of Murine Endothelial Progenitor Cellsin Vitro. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 933-943.	2.4	66
78	Vascular MMP-9/TIMP-2 and Neuronal MMP-10 Up-Regulation in Human Brain after Stroke: A Combined Laser Microdissection and Protein Array Study. Journal of Proteome Research, 2009, 8, 3191-3197.	1.8	93
79	Neuroprotective Effects of Overexpressing Tissue Inhibitor of Metalloproteinase TIMP-1. Journal of Neurotrauma, 2009, 26, 1935-1941.	1.7	103
80	Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome. Current Neurovascular Research, 2009, 6, 246-251.	0.4	18
81	Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Medicine, 2008, 34, 1384-1392.	3.9	77
82	Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. Journal of Leukocyte Biology, 2008, 84, 207-214.	1.5	118
83	Caspase-3 is related to infarct growth after human ischemic stroke. Neuroscience Letters, 2008, 430, 1-6.	1.0	36
84	Multiphasic roles for matrix metalloproteinases after stroke. Current Opinion in Pharmacology, 2008, 8, 82-89.	1.7	212
85	Targeting Extracellular Matrix Proteolysis for Hemorrhagic Complications of tPA Stroke Therapy. CNS and Neurological Disorders - Drug Targets, 2008, 7, 235-242.	0.8	39
86	Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. Stroke, 2008, 39, 2280-2287.	1.0	264
87	MMP-9â€“Positive Neutrophil Infiltration Is Associated to Bloodâ€“Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke. Stroke, 2008, 39, 1121-1126.	1.0	466
88	Fas System Activation in Perihematomal Areas After Spontaneous Intracerebral Hemorrhage. Stroke, 2008, 39, 1730-1734.	1.0	39
89	Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke. Stroke, 2008, 39, 3372-3377.	1.0	204
90	Reduction of hippocampal cell death and proteolytic responses in tissue plasminogen activator knockout mice after transient global cerebral ischemia. Neuroscience, 2007, 150, 50-57.	1.1	25

#	Article	IF	Citations
91	Astrocytic Induction of Matrix Metalloproteinase-9 and Edema in Brain Hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 460-468.	2.4	145
92	Influence of thrombinâ€activatable fibrinolysis inhibitor and plasminogen activator inhibitorâ€1 gene polymorphisms on tissueâ€type plasminogen activatorâ€induced recanalization in ischemic stroke patients. Journal of Thrombosis and Haemostasis, 2007, 5, 1862-1868.	1.9	49
93	Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis. Stroke, 2006, 37, 1205-1210.	1.0	90
94	ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters, 2006, 398, 167-171.	1.0	23
95	Increased Brain Expression of Matrix Metalloproteinase-9 After Ischemic and Hemorrhagic Human Stroke. Stroke, 2006, 37, 1399-1406.	1.0	382
96	Plasma S100B Level After Acute Spontaneous Intracerebral Hemorrhage. Stroke, 2006, 37, 2837-2839.	1.0	58
97	A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke. Stroke, 2005, 36, 1415-1420.	1.0	146
98	Angiogenesis in Symptomatic Intracranial Atherosclerosis. Stroke, 2005, 36, 92-97.	1.0	52
99	Neuroprotective effects of over-expressing tissue inhibitor of metalloproteinase TIMP-1. Journal of Neurotrauma, 0, , 110306202455053.	1.7	4